ADMA Biologics to Present at the 9th International

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ADMA Biologics to Present at the 9th International Respiratory Syncytial Virus (RSV) Symposium

RAMSEY, N.J., Nov. 10, 2014 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA ), announced today that it will be presenting data describing the composition and efficacy in an animal model of its polyclonal IVIG product, RI-002, at the 9th International Respiratory Syncytial Virus (RSV) Symposium, in Cape Town, South Africa. The abstract is titled: "Treatment of Normal and Immune Suppressed Cotton Rats with IVIG Containing High Titer Neutralizing Anti-RSV Antibody."

"The data on RI-002 demonstrated a 99.9% reduction in viral load in both the lung and nasal tissue of cotton rats, an animal model regarded as a surrogate model for human responses to RSV infection," stated Jimmy Mond, M.D., Ph.D., Chief Medical and Scientific Officer for ADMA Biologics. "RI-002 not only eliminated viral load in the lung and nasal tissue but also significantly reduced RSV dissemination to the peripheral organs in the immune suppressed animals, as measured by PCR analysis. Further laboratory analysis of the composition of RI-002 demonstrated that the product contains not only high antibody titers to RSV but also contains significantly elevated levels of antibodies to other respiratory viruses."

The presentation will include:

  • Whole blood analysis data on the immune suppressed cotton rats
  • RI-002 prevents RSV infections in the lungs of immune suppressed cotton rats
  • Reduction of viral load in the lungs of normal and immune suppressed cotton rats treated with RI-002
  • RI-002 reduces RSV dissemination to peripheral organs
  • Histopathology of the lungs of RI-002 treated normal and immune suppressed cotton rats
  • Antibody titer composition; Comparison of antibody levels to other respiratory viruses in RI-002 and standard IVIG

9th International RSV Symposium, Cape Town, South Africa, November 9-12, 2014

Abstract ID # 121 / Poster Presentation # 78

Title: Treatment of Normal and Immune Suppressed Cotton Rats with IVIG Containing High Titer Neutralizing Anti-RSV Antibody

Data Summary: RI-002 induced a 99.9% reduction in viral load in both lung and nasal tissue of normal and immune suppressed cotton rats with the reduction being slightly greater in the tissues of normal animals. RI-002 is manufactured to contain naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae , H. influenza type B etc.) as well as standardized, high levels of neutralizing RSV antibodies and was found to also contain significantly elevated levels of antibodies to other respiratory viruses (p<.002) as compared to a random sampling of seven other standard IVIG products as determined by laboratory analysis.

The poster presentation can be viewed on ADMA Biologics' corporate website under: http://www.admabiologics.com/drug-development...blications .

About ADMA Biologics, Inc.

ADMA is a late stage biopharmaceutical company that develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease or who may be immune-compromised for medical reasons. ADMA also operates ADMA BioCenters a source plasma collection operation which provides ADMA with a portion of its blood plasma for the manufacture of RI-002 as well as generates revenues from the sale of source plasma to third parties. For more information, please visit the Company's website at www.admabiologics.com .

About ADMA's lead product candidate RI-002

ADMA's lead product candidate, RI-002 is a specialty plasma-derived, polyclonal, Intravenous Immune Globulin, or IGIV, derived from human plasma containing naturally occurring polyclonal antibodies (e.g., Streptococcus pneumoniae, H. influenza type B, Cytomegalovirus (CMV), measles, tetanus, etc.) as well as standardized, high levels of antibodies targeted to respiratory syncytial virus (RSV). ADMA is pursuing an indication for the use of this specialty IGIV product for treatment of patients diagnosed with primary immune deficiency diseases, or PIDD. Polyclonal antibodies are the primary component of IGIV products. Polyclonal antibodies are proteins that are used by the body's immune system to neutralize microbes, such as bacteria and viruses. The polyclonal antibodies that are present in RI-002 are expected to prevent infections in immune-compromised patients. The product is currently being evaluated in a Phase III trial in the United States. All patients have completed dosing requirements in the Phase III trial and continue in follow-up. The primary endpoint data will be announced prior to December 31, 2014.  

Cautionary Statement Regarding Forward-Looking Information

This press release contains "forward looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "target," "anticipate," "plan," "planning," "expect," "believe," "will," "will likely," "should," "could," "would," "may" or, in each case, their negative, or words or expressions of similar meaning. These forward-looking statements include, but are not limited to, statements concerning the timing, progress and results of the clinical development, the availability of preliminary data, the reporting of data, regulatory processes, potential clinical trial initiations, potential investigational new product applications, biologics license applications, expansion plans, the achievement of clinical and regulatory milestones, build out, opening and regulatory approval of plasma facilities, commercialization efforts of the Company's product candidate(s), trends relating to demand for source plasma and our ability to sustain the listing of our common stock on the NASDAQ Capital Market. Forward-looking statements are subject to many risks and uncertainties that could cause our actual results and the timing of certain events to differ materially from any future results expressed or implied by the forward-looking statements, including, but not limited to, the risks listed under the heading "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the U.S. Securities and Exchange Commission on March 28, 2014 and our other filings with the U.S. Securities and Exchange Commission including, among other things, risks as to whether any preliminary data will, if and when available, be encouraging, positive or will otherwise lead to an effective or approved product, whether we will be able to demonstrate efficacy or gain necessary approvals to market and commercialize any product, whether we will meet any of our clinical or regulatory milestones, open any new facilities, changes in supply and demand for source plasma, whether we will be able to sustain the listing of our common stock on the NASDAQ Capital Market and whether we will meet any timing targets expressed by the Company. Therefore, current and prospective security holders are cautioned that there also can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent to the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation or warranty by ADMA or any other person that the objectives and plans of ADMA will be achieved in any specified time frame, if at all. Except to the extent required by applicable laws or rules, ADMA does not undertake any obligation to update any forward looking statements or to announce revisions to any of the forward-looking statements.

Brian Lenz VP & Chief Financial Officer 201-478-5552

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Circuit Adds Gabe Klein as Microtransit Expansion Adviser

Updated Category News Views 29

Municipal mobility is a slow, political grind, not a shiny-app contest, and Circuit’s decision to add Gabe Klein to its board looks aimed squarely at that reality. The all-electric microtransit operator has brought aboard somebody who has worked inside the machinery of city government, federal transportation policy, electrification, venture investing, and transportation...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 256

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Breakthrough T1D Gala Puts Research Progress First

Updated Category News Views 5

One person living without insulin after a cell-therapy trial is the detail that cuts through all the ballroom polish tonight. Breakthrough T1D's 53rd Annual New York City Promise Gala lands at the Plaza Hotel during National Diabetes Awareness Month, and it carries a message worth handling carefully: research can produce extraordinary outcomes, but one participant's...

Continue Reading
LRM Adds Two IND Studies Testing Injectable PDGF in Skin

Updated Category News Views 14

Under-eye medicine has a nasty habit of outrunning the evidence, which makes LRM's decision to put injectable rhPDGF-BB through more formal study worth watching. Lynch Regenerative Medicine has announced two FDA-accepted INDs for investigator-initiated clinical trials: one examining what the material does inside facial skin, the other testing it for infraorbital...

Continue Reading
COPD Support Program Targets a Costly Care Gap Today

Updated Category News Views 129

Breathing trouble gets shrugged off far too easily, and that casual mistake has consequences. World COPD Day puts chronic obstructive pulmonary disease back in view, with the American Lung Association emphasizing a free Lung Health Navigator program for people living with COPD, their caregivers and families. This is not flashy medicine or a miracle-cure pitch. It is...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 91

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Anycubic Pushes Toward a Smoother 3D Printing Ecosystem

Updated Category News Views 51

Friction Is the Enemy in Consumer 3D Printing A printer that makes a beautiful object only after three failed attempts is not a consumer product; it is a weekend argument with plastic. That is the useful lens for Anycubic's Formnext 2026 showing in Frankfurt on November 18. The company is not merely rolling out FDM and resin machines at Booth F01 in Hall 12.0. It is...

Continue Reading
Oracle Takes AI to Construction's Messy Project Middle

Updated Category News Views 157

A stalled drywall inspection can wreck a schedule faster than any glossy AI pitch can repair it. That is the grimy, practical corner Oracle is aiming at with its latest Oracle Primavera Cloud upgrades: the daily hunt for answers, the repeated logging of familiar risks, and the finger-pointing that starts when a milestone is suddenly in danger. This is not a chatbot being...

Continue Reading
Abacus Global Faces Scrutiny Over Accounting Practices

Updated Category News Views 265

Storm Clouds Gather over Abacus Global Management If it ain't one thing, it's another—at least that's what folks holding the bag with Abacus Global (ABX) are thinking right now. News of a pending investigation has dropped like a lead balloon, and the air is thick with scrutiny over their financial dealings. We're jawing about related-party transactions now under the...

Continue Reading
Ampace Fire Test Gives Data Centers Useful Evidence

Updated Category News Views 134

Battery cabinets are becoming the awkward guest in the AI data-center boom: absolutely necessary, expensive to install, and nobody wants to discover their failure behavior during a real emergency. Ampace’s newly presented PU100 large-scale fire-test results deserve attention for that reason. This is not a magic safety stamp, and the company says the findings apply only...

Continue Reading

Top 5 Most Recently Viewed Articles

Jøtul Group's Financial Challenges and Strategic Response

Updated Category News Views 138

Understanding the Jøtul Group's Financial Landscape The Jøtul Group is a major player in the fireplace market, known for its exceptional range of products that cater to various consumer preferences. Founded in 1853, this company proudly represents some of Europe's most reputable brands, including Jøtul, Scan, and Ravelli. Each brand encapsulates a unique design...

Continue Reading
Capri Holdings Limited Faces Legal Scrutiny: What You Need to Know

Updated Category News Views 425

Capri Holdings Limited Under Investigation Capri Holdings Limited, known for its involvement in the luxury fashion sector, has recently come under the spotlight due to an ongoing investigation. This investigation is being led by the Law Offices of Howard G. Smith on behalf of the investors of the company. The core of the inquiry centers around potential violations of...

Continue Reading
eBay's Year-End Performance and 2025 Outlook Highlights

Updated Category News Views 1606

eBay Inc. Financial Performance Overview eBay Inc. has showcased remarkable financial growth in its latest performance report. The company announced substantial revenue figures and gross merchandise volume (GMV) for the last quarter and the full year, reinforcing its position as a leading global commerce platform. Key Financial Highlights of Q4 eBay's revenue reached an...

Continue Reading
Join Us for a Free Webinar on Stepfamily Support Strategies

Updated Category News Views 183

Understanding Stepfamily Dynamics Navigating the complexities of blended families can be challenging, and that is exactly why this free webinar, titled From Conflict to Connection: Navigating Stepfamily Dynamics, offers unparalleled insights for parents and stepparents alike. The event is set to feature expert panelists who specialize in co-parenting and stepfamily...

Continue Reading
Lamb Weston Faces Sharp Decline Amid Nasdaq Rally in Stocks

Updated Category News Views 143

Nasdaq Composite Shows Robust Gains The U.S. stock market experienced a positive trajectory as the Nasdaq Composite surged over 1% on a recent trading day. Investors found motivation in the optimistic outlook surrounding technology shares, which rose by 1.6%. Dow and S&P 500 Performance The Dow Jones Industrial Average reflected a modest uptick of 0.55%, reaching an...

Continue Reading